SVA (Sinovac Biotech) Gross-Profit-to-Asset % : 1.21% (As of Jun. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Sinovac Biotech's annualized Gross Profit for the quarter that ended in Jun. 2024 was $161.0 Mil. Sinovac Biotech's average Total Assets over the quarter that ended in Jun. 2024 was $13,277.5 Mil. Therefore, Sinovac Biotech's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was 1.21%.

Sinovac Biotech Gross-Profit-to-Asset % Historical Data

The historical data trend for Sinovac Biotech's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Gross-Profit-to-Asset % Chart

Sinovac Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

51.96

37.68

196.28

5.24

1.92

Sinovac Biotech Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															12.04	-2.05	-0.69	4.60	1.21

Competitive Comparison of Sinovac Biotech's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Sinovac Biotech's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinovac Biotech's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's Gross-Profit-to-Asset % falls into.

Sinovac Biotech Gross-Profit-to-Asset % Calculation

Sinovac Biotech's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	266.753	/	( (14114.568	+	13657.974)	/ 2 )
	=	266.753	/	13886.271
	=	1.92 %

Sinovac Biotech's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Jun. 2024 ))	/ count )
	=	161.006	/	( (13657.974	+	12896.937)	/ 2 )
	=	161.006	/	13277.4555
	=	1.21 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Sinovac Biotech Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinovac Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085

Website

http://www.sinovac.com

Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.

Executives

Lily Wang	director, 10 percent owner, officer: Chief Financial Officer	300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc	10 percent owner	PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong	director, 10 percent owner, officer: President and CEO
Terry G Bowering	director, 10 percent owner, officer: President, CEO	10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6